As an example, genetic analysis has become an established part in the standard diagnostic workflow of lung squamous cell cancer, and BRAF- and MEK-inhibitors dabrafenib and trametinib are approved as palliative first-line therapy in BRAF-mutated cancer [3]. Here, BRAF is linked to squamous cell lung carcinoma.